Vabicaserin is an 5-HT2C agonist potentially for the treatment of schizophrenia. References: Shen JH, Zhao Y, Rosenzweig-Lipson S, Popp D, Williams JB, Giller E, Detke MJ, Kane JM. A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. J Psychiatr Res. 2014 Jun;53:14-22. doi: 10.1016/j.jpsychires.2014.02.012. PubMed PMID: 24613032.

纯度：≥98%

CAS：887258-94-8